Autres langues Annexin Pharmaceuticals AB

Actions

ANNX

SE0009664154

Temps Différé Nasdaq Stockholm Autres places de cotation 14:49:49 02/05/2024			Varia. 5j.	Varia. 1 janv.
0,296 ^SEK	-1,33%		+7,25%	+13,85%

30/04	Annexin Pharmaceuticals AB (Publ) annonce que l'étude de phase II a été entièrement recrutée avec des signaux positifs	CI
12/04	Annexin Pharmaceuticals AB (publ) publie ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioStock: Annexin's phase II study fully recruited with positive signals	30/04
Annexin Pharmaceuticals AB Announces Phase II Study Fully Recruited with Positive Signals	30/04
Last patient treated in Annexin’s RVO study - promising signals of effect and no safety concerns	25/04
BioStock: Annexin towards completion of phase II study and share issue	18/04
Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2024	12/04
Annexin resolves on a rights issue of SEK 45.1 million guaranteed to 90 percent, subject to approval by the 2024 Annual General Meeting, which has been decided to be brought forward	28/03
BioStock: Strong start for Annexin in 2024	14/02
Annexin Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	09/02
Update on Annexin´s RVO study confirms promising signals of effect	08/02
Annexin Pharmaceuticals AB Provides Update on RVO Study Confirms Promising Signals of Effect	08/02
Annexin presents at Redeye’s Fight Cancer event on January 24	18/01
Annexin announces outcome of the rights issue and resolves on directed issues to guarantors and lenders	18/12
The subscription period in Annexin Pharmaceuticals’ rights issue begins today	30/11
Annexin Pharmaceuticals publishes prospectus in connection with forthcoming rights issue	28/11
First patients treated with higher dose without adverse events in Annexin's RVO study	23/11
Annexin granted additional patent protection in the US	14/11
Annexin Pharmaceuticals AB Announces Additional Patent Protection in the US	14/11
First patient treated in the second dose group in Annexin's RVO study	25/10/23
First patient treated in the second dose group in Annexin's RVO study	25/10/23
Annexin Pharmaceuticals AB Announces First Patient Treated in the Second Dose Group in RVO Study	25/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Annexin Pharmaceuticals AB

Actions

ANNX

SE0009664154

Autres langues

Filtres